Equities Analysts Issue Forecasts for FBRX Q2 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Analysts at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for Forte Biosciences in a research note issued to investors on Wednesday, May 13th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings of ($1.08) per share for the quarter. The consensus estimate for Forte Biosciences’ current full-year earnings is ($4.57) per share. Brookline Capital Markets also issued estimates for Forte Biosciences’ Q3 2026 earnings at ($0.90) EPS, FY2026 earnings at ($4.06) EPS, FY2027 earnings at ($2.89) EPS, FY2028 earnings at ($2.61) EPS, FY2029 earnings at ($7.21) EPS and FY2030 earnings at ($5.59) EPS.

Forte Biosciences (NASDAQ:FBRX) last issued its earnings results on Monday, May 11th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.08).

Several other equities analysts also recently commented on FBRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Forte Biosciences in a research note on Friday, March 27th. Wall Street Zen cut Forte Biosciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 10th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Forte Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Forte Biosciences Stock Down 2.8%

Shares of FBRX opened at $23.96 on Friday. The stock has a market capitalization of $332.80 million, a P/E ratio of -5.16 and a beta of 3.01. Forte Biosciences has a twelve month low of $7.00 and a twelve month high of $35.80. The firm has a fifty day simple moving average of $27.71 and a two-hundred day simple moving average of $25.52.

Institutional Trading of Forte Biosciences

Several large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in Forte Biosciences by 6.5% in the 4th quarter. Royal Bank of Canada now owns 11,986 shares of the company’s stock worth $327,000 after purchasing an additional 733 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Forte Biosciences during the 4th quarter valued at about $27,000. Bank of America Corp DE increased its position in shares of Forte Biosciences by 5,641.8% during the third quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock valued at $47,000 after buying an additional 3,103 shares during the period. Geode Capital Management LLC raised its stake in Forte Biosciences by 6.7% in the second quarter. Geode Capital Management LLC now owns 64,110 shares of the company’s stock worth $829,000 after buying an additional 4,028 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in Forte Biosciences by 23.8% in the third quarter. Envestnet Asset Management Inc. now owns 23,347 shares of the company’s stock worth $350,000 after buying an additional 4,491 shares in the last quarter. Institutional investors own 77.63% of the company’s stock.

More Forte Biosciences News

Here are the key news stories impacting Forte Biosciences this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2026 EPS estimate for Forte Biosciences to ($4.06) from ($4.44), suggesting a slightly better outlook for the current year.
• Positive Sentiment: The firm also improved longer-term earnings estimates, including FY2027 to ($2.89) from ($3.26), FY2028 to ($2.61) from ($2.92), FY2029 to ($7.21) from ($7.49), and FY2030 to ($5.59) from ($6.07), which may signal growing confidence in the company’s future profitability.
• Neutral Sentiment: Brookline also issued fresh quarterly estimates, including Q2 2026 EPS of ($1.08) and Q3 2026 EPS of ($0.90), underscoring that the company is still expected to post losses in the near term.
• Neutral Sentiment: The company is scheduled to release quarterly earnings soon, which likely adds uncertainty and keeps traders focused on the stock. Article Title
• Positive Sentiment: Unusually large options activity showed strong speculation ahead of the report, with investors buying 30,205 call options, far above the normal daily volume. This can sometimes reflect bullish sentiment.
• Negative Sentiment: Despite the upgrades, Forte Biosciences is still expected to report substantial losses, and the company recently missed quarterly EPS expectations, which may weigh on the shares.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.